We want to clarify Thrive Health Solutions’ position on the availability of compounded GLP medications, particularly Tirzepatide and Semaglutide.
Thrive will continue prescribing/offering compounded weight loss medication through our FDA-regulated compounding pharmacy partners as we always have. They’ll also add Pyridoxine, based on physician-prescribed needs like addressing nausea, microdosing, and dose calibration.
The FDA’s decision to remove Tirzepatide and Semaglutide from the drug shortage list doesn’t affect our ability to offer compounded formulations as long as manufacturers supply the Tirzepatide/Semaglutide API to our pharmacy partners for non-commercial use.
Legal Update on Tirzepatide Shortage
Many clinics, our compounding pharmacy partners, and the Outsourcing Facilities Association joined a lawsuit against the FDA for removing Tirzepatide and Semaglutide from the drug shortage list despite their continued unavailability from many wholesalers and pharmacy suppliers.
The FDA granted enforcement discretion based on our preliminary injunction motion, but the court denied it. We immediately appealed. The appeal may take months to determine if the FDA acted lawfully regarding the Tirzepatide/Semaglutide shortage.
For now, business continues. Thrive Health Solutions closely monitors the situation and provides updates. We’ll continue prescribing when appropriate.
